Safety issues with biological therapies for inflammatory bowel disease

Current Opinion in Gastroenterology

Volumn 22, Issue 4, 2006, Pages 370-376

  Van Assche, Gert ^a   Vermeire, Séverine ^a   Rutgeerts, Paul ^a  

^a UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Biological agents; Crohn's disease; Infections; Inflammatory bowel diseases; Safety

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; ETANERCEPT; INFLIXIMAB; LENERCEPT; METHOTREXATE; MLN 02; NATALIZUMAB; PURINE DERIVATIVE; STEROID; TUMOR NECROSIS FACTOR ANTIBODY;

APOPTOSIS; AUTOIMMUNE DISEASE; CANCER REGISTRY; CANCER RISK; CARDIOTOXICITY; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DELAYED HYPERSENSITIVITY; DEMYELINATION; DRUG HYPERSENSITIVITY; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; ENTERITIS; HEART FAILURE; HISTOPLASMOSIS; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOPATHOGENESIS; INFECTION; INFECTION COMPLICATION; INFLAMMATORY DISEASE; LUPUS VULGARIS; MULTIPLE SCLEROSIS; MYELOID LEUKEMIA; NEUROTOXICITY; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OPTIC NEURITIS; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PSORIASIS; RESPIRATORY TRACT INFECTION; REVIEW; RHEUMATOID ARTHRITIS; SEPSIS; TREATMENT CONTRAINDICATION; TUBERCULOSIS; ULCERATIVE COLITIS;

ANTIBODIES, MONOCLONAL; BIOLOGICAL THERAPY; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATORY BOWEL DISEASES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33746239695     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mog.0000231810.87901.e8     Document Type: Review

References (48)

1. Cornillie F, Shealy D, D'Haens G, et al. Infliximab induces potent anti-inflammatory and local immunomodulatory activity but no systemic immune suppression in patients with Crohn's disease. Aliment Pharmacol Ther 2001; 15:463-473.
2. Hanauer SB, Feagan BG, Lichtenstein GR, et al. ACCENT I Study Group. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002; 359:1541-1549.
3. Sands BE, Anderson FH, Bernstein CN, et al. Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med 2004; 350:876-885.
4. Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med 2005; 353:2462-2476. This is a report of the first large placebo controlled trial with infliximab in active ulcerative colitis demonstrating both efficacy and safety of the anti-TNF agent in this indication.
5. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345: 1098-1104.
6. Wallis RS, Broder M, Wong J, et al. Reactivation of latent granulomatous infections by infliximab. Clin Infect Dis 2005; 41:S194-S198.
7. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52:3403-3412.
8. Young JD, McGwire BS. Infliximab and reactivation of cerebral toxoplasmosis. N Engl J Med 2005; 353:1530-1531.
9. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 2004; 53:849-853.
10. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology 2004; 126:19-31.
11. Lichtenstein GR, Cohen RD, Feagan BG, et al. Safety of inflixmab and other Crohn's disease therapies: Updated Treat registry data with over 10,000 patient-years of follow-up [abstract]. Gastroenterology 2005; 128 (S2): A580.
12. Miller DH, Khan OA, Sheremata WA, et al. A controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2003; 348:15-23.
13. Sandborn WJ, Colombel JF, Enns R, et al. International Efficacy of Natalizumab as active Crohn's Therapy (ENACT-1) Trial Group; Evaluation of Natalizumab as continuous Therapy (ENACT-2) Trial Group. Natalizumab induction and maintenance therapy for Crohn's disease. N Engl J Med 2005; 353:1912-1925. This reports on a large placebo-controlled trial demonstrating efficacy short term and long term of the selective adhesion molecule inhibitor natalizumab in active Crohn's disease. The trial showed a clear steroid-sparing effect.
14. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta 1a for multiple sclerosis. N Engl J Med 2005; 353:369-374.
15. Langer-Gould A, Atlas SW, Green AJ, et al. Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 2005; 353:375-381.
16. Van Assche G, Van Ranst M, Sciot R, et al. Progressive multifocal leukoencephalopathy after natalizumab therapy for Crohn's disease. N Engl J Med 2005; 353:362-368.
17. Berger JR, Koralnik IJ. Progressive multifocal leukencephalopathy and natalizumab: unforeseen consequences. N Engl J Med 2005; 353:414-416. This is a review of the current state of understanding regarding PML and the possible link of JC virus replication with anti-integrin agents.
18. Ransohoff RM. Natalizumab and PML [letter]. Nat Neurosci 2005; 8:1275.
19. Marchai L, D'Haens G, Van Assche G, et al. The risk of post-operative complications associated with infliximab therapy for Crohn's disease: a controlled cohort study. Aliment Pharmacol Ther 2004; 19:749-754.
20. Colombel JF, Loftus EV Jr, Tremaine WJ, et al. Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004; 99:878-883.
21. Aberra FN, Lewis JD, Hass D, et al. Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology 2003; 125:320-327.
22. Jarnerot G, Hertervig E, Friis-Liby I, et al. Infliximab as rescue therapy in severe to moderately severe ulcerative colitis: a randomized, placebo-controlled study. Gastroenterology 2005; 128:1805-1811. This was the first placebo-controlled trial showing a decrease in colectomy rates with infliximab in patients with moderate to severe steroid refractory ulcerative colitis.
23. Hwang WYK, Foote J. Immunogenicity of engineered antibodies. Methods 2005; 36:3-10. This is a concise review of the technology behind engineered therapeutic proteins.
24. Baert F, Noman M, Vermeire S, et al. Influence of immunogenicity on the long term efficacy of infliximab in Crohn's disease. N Engl J Med 2003; 348:601-608.
25. Farrell RJ, Alsahli M, Jeen YT, et al. Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn's disease: a randomized controlled trial. Gastroenterology 2003; 124:917-924.
26. Reich K, O Nestle F, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre double-blind trial. Lancet 2005; 366:1367-1374.
27. Rutgeerts P, Van Assche G, Vermeire S. Optimizing anti-TNF treatment in inflammatory bowel disease. Gastroenterology 2004; 126:1593-1610.
28. Su CG, Lichtenstein GR. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease. Gastroenterology 2003; 125: 1544-1546.
29. Hanauer SB, Wagner CL, Bala M, et al. Incidence and importance of antibody responses to infliximab after maintenance or episodic treatment in Crohn's disease. Clin Gastroenterol Hepatol 2004; 2:542-553.
30. Sandborn WJ, Loftus EV. Balancing the risks and benefits of infliximab in the treatment of inflammatory bowel disease. Gut 2004; 53:780-782.
31. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005; 352:2499-2507.
32. Schreiber S, Rutgeerts P, Fedorak RN, et al. CDP870 Crohn's Disease Study Group. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease. Gastroenterology 2005; 129: 807-818.
33. Youdim A, Vasiliauskas EA, Targan SR, et al. A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis 2004; 10:333-338.
34. Sandborn WJ, Hanauer S, Loftus EV Jr, et al. An open-label study of the human anti-TNF monoclonal antibody adalimumab in subjects with prior loss of response or intolerance to infliximab for Crohn's disease. Am J Gastroenterol 2004; 99:1984-1989.
35. Hanauer SB, Sandborn WB, Rutgeerts P, et al. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-1 trial. Gastroenterology 2006; 130:323-333.
36. Kress A. Adalimumab for use in the treatment of rheumatoid arthritis: clinical review. Abott laboratories Biologic Licensing Application, 1-136.12-24-02. Office of Therapeutics Research and Review, Division of Clinical Trial Design and Analysis; Immunology and Infectious Diseases Branch. Rockville: Food and Drug Administration; 2002.
37. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab a fully human anti-tumor necrosis factor monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate. The ARMADA Trial. Arthritis Rheum 2003; 48:35-45.
38. Anderson PJ. Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles. Semin Arthritis Rheum 2005; 34 (S1):19-22.
39. Askling J, Brandt L, Lapidus A, et al. Risk of haematopoietic cancer in patients with inflammatory bowel disease. Gut 2005; 54:617-622. This is the most recent analysis of the risk of lymphoma in an IBD patient cohort compared with controls. The data suggest that the risk is only marginally increased and only early in the disease course, which indicates that there is no link with longstanding use of immunosuppressive drugs.
40. Reijasse D, Le Pendeven C, Cosnes J, et al. Epstein-Barr virus viral load in Crohn's disease: effect of immunosuppressive therapy. Inflamm Bowel Dis 2004; 10:85-90.
41. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46:3151-3158.
42. Vermeire S, Noman M, Van Assche G, et al. Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study. Gastroenterology 2003; 125:32-39.
43. Atzeni F, Turiel M, Capsoni F, et al. Autoimmunity and anti-TNF-α agents. Ann N Y Acad Sci 2005; 1051:559-569. This is a concise review of the reports on induction of auto-antibodies associated with the use of anti-TNF agents in various immune mediated disorders.
44. Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 2003; 9: 176-178.
45. Nancey S, Blanvillain E, Parmentier B, et al. Infliximab treatment does not induce organ-specific or nonorgan-specific autoantibodies other than antinuclear and anti-double-stranded DNA autoantibodies in Crohn's disease. Inflamm Bowel Dis 2005; 11:986-991.
46. Anonymous. TNF neutralization in MS: results of randomized placebo-controlled multicenter study. The Lenercept Mulitple Sclerosis Study Group and the University of British Columbia MS/MRI Analysis group. Neurology 1999; 53:457-465.
47. Gupta G, Gelfand JM, Lewis JD. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 2005; 129: 819-826.
48. Dinesh K, McMahon M, Furst DE. Anti-tumor necrosis factor alpha therapy and heart failure. Arthritis Rheum 2004; 50:1040-1050.